Pharmacokinetics/pharmacodynamics of marbofloxacin in a Pasteurella multocida serious murine lung infection model by Ying Qu et al.
RESEARCH ARTICLE Open Access
Pharmacokinetics/pharmacodynamics of
marbofloxacin in a Pasteurella multocida
serious murine lung infection model
Ying Qu†, Zhenzhen Qiu†, Changfu Cao, Yan Lu, Meizhen Sun, Chaoping Liang and Zhenling Zeng*
Abstract
Background: Marbofloxacin is a third-generation fluoroquinolone developed solely for veterinary medicine with a
broad spectrum of antibacterial activity against some Gram-positive and most Gram-negative bacteria, including
the bovine respiratory tract pathogen, Pasteurella multocida. The objective of our study was to elucidate the
pharmacokinetics and pharmacodynamics of marbofloxacin in a Pasteurella multocida infected murine lung model, and
to estimate the magnitudes of pharmacokinetics-pharmacodynamics parameters associated with various effects.
Results: The pharmacokinetic studies revealed marbofloxacin kinetics in infected mice were linear over a dose ranging
from 1.25 to 10 mg/kg of body weight. The protein binding in the plasma of neutropenic infected mice was 29.77 %.
The magnitudes of the ratio of the free-drug area under the concentration-time curve over 24 h to MIC (fAUC0-24h/MIC)
associated with static effect, a 2 log10 reduction and a 3 log10 reduction of bacterial counts were 40.84, 139.34, and
278.08 h, respectively.
Conclusions: Based on the dose range study, marbofloxacin exhibited concentration-dependent killing and the fAUC/
MIC was the PK/PD index that correlated best with efficacy (R2 = 83 %). On the basis of a bactericidal effect goal of
fAUC0-24h/MIC of 278.08 h, if marbofloxacin is used for the treatment of P. multocida serious lung infection with an
MIC90 of 0.12 μg/ml, the current dose (2 mg/kg) would fail to achieve a bactericidal effect. It would benefit from higher
doses (4 ~ 6 mg/kg) than those commonly used in clinical practice.
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Background
Pasteurella multocida is a pathogenic Gram-negative
bacterium that is a common inhabitant of the upper re-
spiratory tract of calves [1]. It may cause a wide spectrum
of diseases ranging from septicemia to pneumonia [2].
Marbofloxacin, a synthetic third-generation fluoro-
quinolone has been developed solely for veterinary use
and displays a broad spectrum of antimicrobial activity
against most Gram-negative and some Gram-positive bac-
teria [3–5]. It has been approved for the treatment of re-
spiratory, urinary tract, soft tissue and dermatological
infections in cattle, pigs, dogs, and cats [6–8].
Using pharmacokinetics and pharmacodynamics (PK-PD)
principles is a widely accepted approach for optimization
of antimicrobial therapy [9, 10]. Three principal PK-PD
surrogate markers of efficacy (AUC0→24h/MIC, Cmax/
MIC, T>MIC) have been used as a basis for dose
optimization by quantifying the potency and efficacy of
antimicrobials against target pathogens [11, 12].
Previous studies have demonstrated that marbofloxacin
displays a concentration-dependent killing mechanism of
action and the AUC24h/MIC surrogate marker is the
PK-PD parameter best linked with efficacy [3, 13, 14].
There are numerous studies describing the characteristics
of the time-kill profiles and growth inhibition of marbo-
floxacin against P. multocida. However, the pharmacody-
namic properties of marbofloxacin were elucidated by
using in vitro dynamic models or ex vivo using calf serum,
exudate, and transudate harvested from a tissue cage
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model. The results were established by modelling in vitro
time-kill data with pharmacokinetic properties of marbo-
floxacin. The goal of our studies was to characterize the
in vivo activity of marbofloxacin in a mouse model of
serious P. multocida infection, and to determine the mag-
nitude of PK/PD parameter predictive of efficacy. Today,
animal pharmacokinetic-pharmacodynamic (PK-PD) in-
fection models serve as a cornerstone of the preclinical
assessment process for antibacterial agents. The mag-
nitude of exposure identified for bacterial stasis in im-
munocompromised animals was similar to the exposure
threshold associated with good clinical outcomes for pa-
tients treated with oritavancin or linezolid for bacteremia
[15]. A neutropenic mouse model is always used in human
medicine research [16]. We can exclude the host defense
and only analyze the effects of drug on bacteria with this
model, which is known to be relevant for drawing conclu-
sions about drug PK/PD with humans [16, 17].
Methods
Bacteria and antibiotic
P. multocida strain CVCC 411, isolated from a buffalo that
died from hemorrhagic septicemia, was obtained from
National Veterinary Microorganism Strains Preservation
Management Centre (Beijing, China). Marbofloxacin was a
10 % injectable aqueous solution obtained from Veterinary
Pharmaceutical Corporation (Yuanzhen Co., Ltd, Hebei,
China). Marbofloxacin reference standard was purchased
from Dr. Ehenstorfer GmbH company (Germany) and
ofloxacin was aquired from the National Institute for Food
and Drug Control (Beijing, China).
In vitro susceptibility testing
The MIC of marbofloxcin was determined by broth
microdilution methodology according to the Clinical and
Laboratory Standards Institute (CLSI) recommended me-
thods and quality control requirements. Susceptibility test-
ing was performed in triplicates.
Inoculum preparation
A few colonies of freshly grown P. multocida CVCC 411
from Tryptic Soy agar (Guangdong Huankai Microbial Sci.
& Tech. Co., Ltd., Guangzhou, China) plates supplemented
with 5 % sheep blood (Puboxin Biotechnology Co., Ltd.,
Beijing, China) were cultured in Mueller–Hinton II broth
(Becton Dickinson, Sparks, MD, USA) with shaking at
200 rpm at 37 °C for 10 h (final cell count approximately
109 CFU/mL). Bacteria were collected by centrifugation at
3,000 g for 10 min and re-suspended in 0.9 % NaCl to ob-
tain a final suspension containing 1010 CFU/mL. This sus-
pension was then diluted 100 times to obtain a bacterial
concentration at 108 CFU/mL.
Animals
Six-week-old, specific-pathogen-free, female ICR mice
(Medical Experimental Animal Center of Guangdong
Province, Guangzhou, China) weighing between 22 and
24 g were used for the experiments. All animal studies
were approved by the Animal Research Committees of
South China Agriculture University. The animals were
maintained in accordance with the American Association
for Accreditation of Laboratory Animal Care criteria. All
sections of this report adhere to the ARRIVE Guidelines
for reporting animal research. A completed ARRIVE
guidelines checklist is included in Additional file 1.
Neutropenic mouse lung infection model
Before the mice were infected with P.multocida using
endotracheal intubation, the mice were rendered neutro-
penic by injecting cyclophosphamide (Aladdin Co., Ltd.,
Shanghai, China) intraperitoneally 4 days (150 mg/kg of
body weight) and 1 day (100 mg/kg of body weight) [18].
On the 6th day, the mice were anesthetized by injecting
1 % pentobarbital sodium (XiangBo Biotechnology Co.,
Ltd., Guangdong, China) solution (50 mg/kg) intraperito-
neally. A simple 22G “Y” type intravenous catheter (PUYI
Medical Devices Co., Ltd., Shanghai, China) that consisted
of an IV catheter connected to a PVC flexible pipe was
used to intubate the mice. A 50 μL saline suspension
of P. multocida CVCC411 containing 108 CFU/mL de-
scribed above was injected into the PVC flexible pipe and
then kept horizontal. The anesthetized mouse was placed
on an adjustable-angled support suspended by its upper
incisors; the tongue was gently pulled out of the mouth.
Using a light source illuminating the neck of the mouse,
we can clearly observe the glottis opening and then clos-
ing alternately. The catheter was inserted through the
glottis and if the catheter was successfully inserted into
the trachea, the inoculum in the PVC flexible pipe would
fluctuate following the breath of the mouse. We used
0.8 mL gas to thrust the 50 μL bacterial inoculum into the
lung (this process operated approximately for 2 s), there-
after, mouse was held in a vertical position for 15 s. Anti-
microbial therapy was initiated 10 h when the mice showed
lethargy and dyspnea after the infection of P. multocida.
PK studies
The neutropenic mice were infected with P. multocida as
described above, and 10 h later were administered with
single subcutaneous doses of 1.25, 2.5, 5, or 10 mg/kg
marbofloxacin in 0.2 mL volumes. Groups of four mice
were each sampled by retro-orbital puncture at 0.083,
0.25, 0.5, 0.75, 1, 2, 4, 6, 8, 12 and 24 h after dosing. The
total volume collected from each individual mouse was
less than 10 % of the total blood volume, namely each
mouse was sampled about three times and each time a
blood sample of approximately 0.25 mL was obtained.
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Blood samples were centrifuged at 7,000 g for 10 min at
4 °C, the plasma were removed and stored at −20 °C until
the assay. Marbofloxacin concentrations were determined
using a HPLC method with fluorescence detection (excita-
tion and emission wavelengths were 295 nm and 500 nm).
Briefly, marbofloxacin was extracted as follows: 0.1 mL
plasma, spiked with 10 μL internal standard-ofloxacin,
was added to 3 mL of trichloromethane and vortexed for
30s. The organic layer was collected after centrifugation
for 10 min at 3,000 g, and then concentrated to dryness
under a stream of nitrogen. A 0.2 mL mobile phase was
used to re-suspend the dried sample and a 20 μL aliquot
was taken and injected into HPLC for analysis. The
standard calibration curve of marbofloxacin was linear for
concentrations ranging from 0.01 to 5 μg/mL. The intra-
day and inter-day precision levels varied from 4.13 % to
7.18 % and from 6.70 % to 8.24 %, respectively. The pro-
tein binding in the plasma of neutropenic infected mice
was determined by ultrafiltration methods. The level of
binding was measured with marbofloxacin concentrations
of 0.05, 0.5 and 5 μg/mL.
PD parameter determination
The neutropenic mice were infected with P. multocida
using endotracheal intubation as previously described;
we used twenty control mice which were not treated to
assess the growth of P. multocida in the lungs. Groups
of five mice were sacrificed 2, 5, 10 and 24 h after the
inoculation and the amount of bacteria in the lungs was
counted. The neutropenic mice were infected with P.
multocida 10 h prior to the start of therapy. Groups of
five mice were treated for 24 h with single marbofloxacin
doses from 0.625 to 10 mg/kg/24 h (0.625, 1, 1.25, 2, 2.5,
4, 5, 8, 10 mg/kg). The drug was administered subcutane-
ously in 0.2 ml volumes. The treated mice were humanely
killed 24 h after initiation of treatment; the lungs were
aseptically removed and homogenized in 5 mL of steril-
ized saline, individually. Bacterial counts of each lung were
determined by serial 10-fold dilutions of homogenates,
20 μL drops of the successive dilutions were dropped in
triplicate on a TSA (supplemented with 5 % sheep blood)
surface and waited to dry before incubating at 37 °C. If the
bacterial counts were less than 250 CFU/lung, 100 μL of
the homogenates were plated in triplicate on agar. The
lowest level of detection was 50 CFU/lung (equivalent to
one colony per plate). The untreated control mice were
humanely killed just before treatment and after 24 h.
PK and PK/PD analysis
The data obtained with a single subcutaneous injection
of 1.25, 2.5, 5 and 10 mg/kg marbofloxacin were ana-
lyzed separately using WinNonlin version 5.2 (Pharsight
Corporation). Marbofloxacin concentration-time data
were best described using the noncompartment model
with extravascular input. According to dose proportio-
nality from the obtained PK parameters, we used them
to estimate the AUC0-24h, Cmax for each tested mabo-
floxacin dosing for which no kinetics were deter-
mined. The PK/PD analysis was performed by using the
inhibitory effect Emax model. This model is described by
the following equation: E = Emax-(Emax-E0)*(C/(EC50 + C)),
where E is the change in log10CFU/lung after 24 h in
treated mice compared to the initial log10CFU/lung in un-
treated control mice; Emax is the log change in CFU per
lung, comparing 0 and 24 h in the untreated control mice;
E0 is the change in log10CFU/lung between the treated
mice with untreated mice after the 24 h period of the
study, when the detection limit is reached; C is the PK/PD
parameter (e.g. fAUC/MIC, fCmax/MIC, fT>MIC); EC50 is
the C value at which 50 % of the maximal antibacterial ef-
fect is produced. These PD parameters were calculated
using the nonlinear regression program (WinNonlin,
Pharsight Corporation).
Results
In vitro susceptibility testing
The MIC of marbofloxacin for P. multocia CVCC 411 was
0.031 μg/mL by the broth microdilution methodology.
Pharmacokinetic study
The time-concentration curves of marbofloxacin in the
plasma of infected neutropenic mice after single sub-
cutaneous doses of 1.25, 2.5, 5, and 10 mg/kg are shown
in Fig. 1. The PK data obtained with different marbo-
floxacin doses were analyzed using a noncompartment
model with extravascular input, and the obtained values
of marbofloxacin pharmacokinetic parameters are shown
in Table 1. The PK parameters were dose-dependent,
where the AUC/dose values for the escalating single doses
ranged from 2.29 to 2.41, and the Cmax/dose values ranged
from 0.43 to 0.53. The plasma protein binding of mar-
bofloxacin at concentrations of 0.05, 0.5, 5 μg/ml were
33.04 ± 2.37 %, 25.70 ± 1.18 %, 30.55 ± 0.10 %. And the
mean value of 29.77 % of the plasma protein binding was
used to calculate the free plasma concentrations. Thus, we
can obtain the free PK parameter values.
Lung infection model
The intubation method in this study was based on other
endotracheal intubation methods [19] and improved by
using a 22G “Y” type intravenous catheter. This method
features well in terms of repeatability, and it is non-
invasive, inexpensive and rapid. About 6.81 log10CFU/
mouse was inoculated via the trachea, but by two
hours after the inoculation, the bacterial load in mice
was 6.15 ± 0.21 log10 CFU/lung. Five hours after inocula-
tion the bacterial burden was 6.60 ± 0.15 log10 CFU/lung
and the mice had no clinical signs of infection. Ten hours
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after the inoculation, the mice were lethargic with dyspnea
and the bacterial population reached 7.38 ± 0.19 log10
CFU/lung, and by 24 h after inoculation, the bacterial
population increased to 8.82 ± 0.16 log10 CFU/lung, and
the mice were on the verge of death.
PK/PD analysis
(i) Total bacterial populations. Total bacterial popula-
tions after 24 h of marbofloxacin treatment are reported
in Table 2. At the start of therapy, mice were infected
with 7.12 ± 0.12 log10 CFU/lung of P. multocia CVCC
411. The untreated control mice died in around 24 h
post-challenge and the organisms grew 1.95 ± 0.19 log10
CFU/lung. The relationships between efficacy and each
of the PK/PD indices (fAUC0-24h/MIC, fCmax/MIC) are
shown in Fig. 2. fAUC0-24h/MIC correlated well with
microbiological efficacy (R2 = 0.83), and a similar rela-
tionship was observed for the fCmax/MIC correlated
with efficacy (R2 = 0.82). (ii) PK/PD parameters deter-
mining efficacy: The dose–response relationships with
single doses of marbofloxacin for P. multocia were eval-
uated using inhibitory Effect Emax model. The PK/PD
model parameter estimates for the fAUC0-24h/MIC index
and the values of fAUC0-24h/MIC required for static
effect, 2 and 3 log10 reduction of bacterial burden are
shown in Table 3. The highest dose of 10 mg/kg marbo-
floxacin, corresponding to fAUC0-24h/MIC values of
537.12 h, reduced the bacterial burden by more than 3
log. The fAUC0-24h/MIC values of 91.08 ± 16.49 h,
equivalent to 1.77 ± 0.32 mg/kg for marbofloxacin, per-
formed 50 % of the maximum antibacterial effect.
Discussion
In the current study, we used a neutropenic mouse-lung
model to characterize the PD profiles of marbofloxacin,
a fluoroquinolone of veterinary interest. We infected the
mice with P. multocida, which eventually led to the
development of septicemia, This murine lung infection
model was also used to elucidate the magnitude of the
fAUC0-24h/MIC index required for various effects.
Previous in vitro and in vivo studies demonstrated that
inoculum size influenced the pharmacodynamics of
antimicrobial drugs. Indeed, the different inoculum sizes
were directly inoculated into broth and animals but the
natural growth of the bacterial was not taken into
Fig. 1 Pharmacokinetic profiles of marbofloxacin in neutropenic
mice. The neutropenic mice were infected with P. multocida as
described above, and 10 h later administered with single subcutaneous
doses of 1.25, 2.5, 5, or 10 mg/kg marbofloxacin in 0.2 mL volumes.
Groups of four mice were each sampled by retro-orbital puncture at
0.083, 0.25, 0.5, 0.75, 1, 2, 4, 6, 8, 12, 24 h after dosing. Marbofloxacin
concentrations were determined using a HPLC method with
fluorescence detection. Each symbol represents the mean ± standard
deviation of the levels in the sera of three mice
Table 1 Pharmacokinetic parameters obtained from plasma












1.25 0.66 ± 0.07 0.75 2.92 411.2 5.40
2.5 1.14 ± 0.14 0.75 5.73 420.3 5.23
5 2.13 ± 0.22 0.75 12.05 400.9 5.00
10 4.83 ± 0.30 0.75 23.90 408.9 4.29
Cmax: maximum concentration of drug in plasma
Tmax: time to maximum concentration of drug in plasma
AUC: area under the concentration-time curve
Cl: clearance
T1/2: half-life
Table 2 Total bacterial populations after 24-h exposure to





Bacterial population (mean ± SD)
(log10 CFU/lung)
Untreated controls 0
At start of treatmenta 7.12 ± 0.12
24 h after inoculationb 9.07 ± 0.19
24 h after start of
treatment
**
Single administration 0.625 7.79 ± 0.56
1 6.87 ± 0.91
1.25 6.31 ± 0.74
2 5.20 ± 0.74
2.5 4.97 ± 0.52
4 4.88 ± 0.41
5 4.14 ± 0.49
8 3.64 ± 0.63
10 3.40 ± 0.32
aTotal bacterial population 10 h after the time of infection
b24 h after the inoculation was the time that the mice approached to death,
and the lungs were removed for calculation the bacterial population
**The mice were already dead
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account in these studies [20, 21]. In the present study,
when the mice had slight clinical signs, we administered
marbofloxacin at this time to mimic “conventional”
curative treatment. In an earlier study, Ferran et al. [22]
referred to the later “conventional” curative treatment in
a mouse-lung model of P. multocida infection studies.
Previous in vivo studies had shown that bacterial infec-
tions altered the PK of drugs, including fluoroquinolone
antimicrobials, such as marbofloxacin [16, 21, 23, 24].
We evaluated the PK of marbofloxacin in P. multocida-
infected mice with single subcutaneous doses of 1.25,
2.5, 5, 10 mg/kg. The PK data in Table 2 showed dose-
proportionality for marbofloxacin in P.multocida in-
fected mice, with the AUC and Cmax proportional to the
dose. This dose-proportionality was also previously dem-
onstrated in mice infected with Escherichia coli in the
thighs [20]. In this study, the AUC value of marbofloxa-
cin in mice receiving 10 mg/kg was 23.90 μg.h/ml, which
was in accordance with the AUC values of the mice
receiving 20 mg/kg marboflxacin for late administration
after inoculation of P. multocida (54 μg.h/ml) [22]. The
clearance of 410.33 ± 7.98 ml kg−1 h−1 of the four doses
of marbofloxacin was similar to the clearance reported
in the mice receiving 20 mg/kg marbofloxacin for late
administration after inoculation of P. multocida
(370 ml kg−1 h−1) [22]. The evolution of the disease
induced a lower clearance of marbofloxacin, as pre-
viously observed [20]. The elimination half-life was
4.98 ± 0.49 h for the four doses in infected mice, and the
value was higher in this study than the previously reported
values. The production of endotoxins by gram-negative
bacterial was shown to decrease the activity of hepatic
metabolism, the renal blood flow, and the glomerular
filtration rate, and might be the explanation for the
alteration of the drug elimination [20]. Both organisms are
gram-negative so endotoxins could have played a role in
both infections. Since single-injection cures are of major
importance to the cattle industry, we only administered a
single treatment within 24 h in this study, rather than the
multiple dosing regimens generally employed in other
in vivo studies.
Several animal infection models have identified that
the fluoroquinolones display the characteristics of
concentration-dependent killing and the AUC/MIC ratio
is the PK/PD index most predictive of the antibacterial
effect [16, 25]. Based upon R2 values and visual examin-
ation of the fits, data from this lung infection model
study confirmed that fAUC0-24h/MIC and fCmax/MIC
well correlated with efficacy of marbofloxacin against
P. multocida. In the current investigation, the fAUC0-24h/
MIC required to produce a static effect, 2 log10 reduction
and 3 log10 reduction in bacterial counts against P.
Fig. 2 Relationships between marbofloxacin’s fAUC24/MIC, fCmax/MIC and microbiological efficacy for pasteurella multocida. The neutropenic mice
were infected with P. multocida 10 h prior to the start of therapy. Groups of five mice were treated for 24 h with single marbofloxacin doses from
0.625 to 10 mg/kg/24 h (0.625, 1, 1.25, 2, 2.5, 4, 5, 8, 10 mg/kg). After 24 h of therapy, the amount of bacteria in the lungs was counted. The
figure above reveals the relationships of marbofloxacin’s fAUC24/MIC and fCmax/MIC for pasteurella multocida CVCC 411 with the change in the
log10 number of CFU/lung after 24 h of therapy. Each symbol represents a single lung tissue per mouse. R
2 is the correlation coefficient
Table 3 The PK/PD parameter estimates for the fAUC/MIC index
and the fAUC/MIC required for various antibacterial effects
Parameter Unit Mean ± SD
Emax log10CFU/lung 2.08 ± 0.26
E0 log10CFU/lung −4.67 ± 0.32
fAUC/MIC for EC50 h 91.08 ± 16.49
fAUC/MIC for static effect h 40.84
fAUC/MIC for 1 log10 kill h 76.88
fAUC/MIC for 2 log10 kill h 139.34
fAUC/MIC for 3 log10 kill h 278.08
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multocida were 40.84, 139.34, 278.08 h, respectively,
which were higher than observed in previous studies.
Potter et al. [14] found that the mean AUC24h/MIC values
of marbofloxacin for no reduction, 3 log10 and 4 log10 re-
ductions in bacterial count from the initial inoculum
count, based on serum MICs, were 48.6, 64.9, and 74.8 h
for P. multocida. Moreover, the corresponding values were
24.35, 44.24, and 64.36 h in the studies reported by
Illambas et al. [13]. In this present study, the initial
bacterial load (7.12 ± 0.12log10CFU/lung) was higher than
a medium inoculum count of 5*106 CFU/ml routinely
used in time-kill studies. As previously observed, pathogen
load impacts the drug concentration required for
inhibition of growth, with a general expectation of a
higher dosage requirement for higher pathogen loads [13].
Therefore, the higher initial P. multocida load in this
murine lung infection model might explain the higher
fAUC/MIC values for various magnitudes of effect. Pre-
vious reports found that for a low and a high inoculum of
bacterial in the mouse infection model, a low and a high
value of AUC24/MIC, respectively, were needed for
bactericidal effect [20, 21]. These findings fully con-
firmed that the inoculum size influenced the values of
pharmacokinetic/pharmacodynamic indices.
Conclusions
The present study showed that fAUC/MIC and fCmax/
MIC well correlated with efficacy of marbofloxacin
against P. multocida. The value of the 24 h static dose
was a fAUC0-24h/MIC of 40.84 h and when the ratio
reached 91.08 h, rates of microbiologic cure approached
50 %. Moreover, the results showed that a bactericidal
action was not achieved until the fAUC0-24h/MIC had
reached 278.08 h.
In conclusion, the antimicrobial PD in humans may be
predicted from studies with animal models. According
to the pharmacokinetic properties and the PK/PD pa-
rameters, the neutropenic mouse model has successfully
predicted the dose of therapy in human medicine area
[16, 17, 25]. Therefore, in this study, the recommended
dose of marbofloxacin of 2 mg/kg for cattle against
bovine respiratory disease produced a 24 h AUC of
10-15 μg.h/ml [5]. On the basis of a bactericidal effect
goal of fAUC0-24h/MIC of 278.08 h, this model would
predict that if marbofloxacin is used for the treatment of
P. multocida serious lung infection with an MIC90 of
0.12 μg/ml, the current dose would fail to achieve a
bactericidal effect. It would benefit from higher doses
(4 ~ 6 mg/kg) than those commonly used in clinical prac-
tice. However, with drugs from the fluoroquinolone class,
the presence of neutrophils can enhance antimicrobial
activity by up to a factor of four to six [26]. Thus the
above dosage was a theoretical value, which should further
validate in clinical or field study.
Additional file
Additional file 1: The ARRIVE Guidelines Checklist. Animal Research:
Reporting In Vivo Experiments. (PDF 391 kb)
Abbreviations
P. multocida: Pasteurella multocida; MIC: minimum inhibitory concentration;
PK: Pharmacokinetics; PD: Pharmacodynamics; AUC: area under the curve;
Cmax: peak serum (or plasma) concentration; fAUC24h/MIC: the ratio of area
under the free plasma/serum concentration-time curve over 24 h to MIC;
fCmax/MIC: the ratio of free peak serum (or plasma) concentration measured
in vivo to MIC determined in vitro; CFU: Colony forming unit; CVCC: China
veterinary culture collection; HPLC: high performance liquid chromatography;
CLSI: clinical and laboratory standards institute.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
YQ and ZQ contributed equally to this study. YL; ZS; PL collected and
analysis samples FC; LZ and YQ analysis data. YQ and ZQ designed and
conducted the experiment. YQ drafted the manuscript. All authors read and
approved the final manuscript.
Acknowledgements
This work is supported financially by the National Natural Science Foundation
of China (grant 31372480) and the National Key Basic Research Program of
China (grant 2013CB127200).
Received: 21 April 2015 Accepted: 24 November 2015
References
1. Dabo SM, Taylor JD, Confer AW. Pasteurella multocida and bovine
respiratory disease. Anim Health Res Rev. 2007;8(2):129–50.
2. Tabatabaei M, Liu Z, Finucane A, Parton R, Coote J. Protective Immunity
Conferred by Attenuated aroA Derivatives of Pasteurella multocida B:2
Strains in a Mouse Model of Hemorrhagic Septicemia. Infect Immun.
2002;70(7):3355–62.
3. Shan Q, Wang J, Yang F, Ding H, Liang C, Lv Z, et al. Pharmacokinetic/
pharmacodynamic relationship of marbofloxacin against Pasteurella
multocida in a tissue-cage model in yellow cattle. J Vet Pharmacol Ther.
2014;37(3):222–30.
4. Thomas A, Nicolas C, Dizier I, Mainil J, Linden A. Antibiotic
susceptibilities of recent isolates of Mycoplasma bovis in Belgium.
Vet Rec. 2003;153(14):428–31.
5. Valle M, Schneider M, Galland D, Giboin H, Woehrle F. Pharmacokinetic and
pharmacodynamic testing of marbofloxacin administered as a single
injection for the treatment of bovine respiratory disease. J Vet Pharmacol
Ther. 2012;35(6):519–28.
6. Dossin O, Gruet P, Thomas E. Comparative field evaluation of marbofloxacin
tablets in the treatment of feline upper respiratory infections. J Small Anim
Pract. 1998;39(6):286–9.
7. Thomas E, Caldow G, Borell D, Davot J. A field comparison of the efficacy
and tolerance of marbofloxacin in the treatment of bovine respiratory
disease. J Vet Pharmacol Ther. 2001;24(5):353–8.
8. Thomas E, Grandemange E, Pommier P, Wessel‐Robert S, Davot J. Field
evaluation of efficacy and tolerance of a 2 % marbofloxacin injectable
solution for the treatment of respiratory disease in fattening pigs. Vet Q.
2000;22(3):131–5.
9. Shan Q, Liang C, Wang J, Li J, Zeng Z. In vivo activity of cefquinome against
Escherichia coli in the thighs of neutropenic mice. Antimicrob Agents
Chemother. 2014;58(10):5943–6.
10. Wang J, Shan Q, Ding H, Liang C, Zeng Z. Pharmacodynamics of
Cefquinome in a Neutropenic Mouse Thigh Model of Staphylococcus
aureus Infection. Antimicrob Agents Chemother. 2014;58(6):3008–12.
11. AliAbadi FS, Lees P. Antibiotic treatment for animals: effect on bacterial
population and dosage regimen optimisation. Int J Antimicrob Agents.
2000;14(4):307–13.
Qu et al. BMC Veterinary Research  (2015) 11:294 Page 6 of 7
12. Mouton JW, Dudley MN, Cars O, Derendorf H, Drusano GL. Standardization of
pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective
drugs. Int J Antimicrob Agents. 2002;19(4):355–8.
13. Illambas J, Potter T, Cheng Z, Rycroft A, Fishwick J, Lees P.
Pharmacodynamics of marbofloxacin for calf pneumonia pathogens. Res
Vet Sci. 2013;94(3):675–81.
14. Potter T, Illambas J, Pelligand L, Rycroft A, Lees P. Pharmacokinetic and
pharmacodynamic integration and modelling of marbofloxacin in calves for
Mannheimia haemolytica and Pasteurella multocida. Vet J. 2013;195(1):53–8.
15. Ambrose PG, Bhavnani SM, Rubino CM, Louie A, Gumbo T, Forrest A, et al.
Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just
for mice anymore. Clin Infect Dis. 2007;44(1):79–86.
16. Andes D, Craig WA. Pharmacodynamics of the New Fluoroquinolone
Gatifloxacin in Murine Thigh and Lung Infection Models. Antimicrob Agents
Chemother. 2002;46(6):1665–70.
17. Higuchi S, Kurosaka Y, Uoyama S, Yoshida K, Chiba M, Ishii C, et al.
Anti-multidrug-resistant Acinetobacter baumannii activity of DS-8587:
In vitro activity and in vivo efficacy in a murine calf muscle infection model.
J Infect Chemother. 2014;20(5):312–6.
18. Andes D, Craig W. In vivo activities of amoxicillin and amoxicillin-clavulanate
against Streptococcus pneumoniae: application to breakpoint
determinations. Antimicrob Agents Chemother. 1998;42(9):2375–9.
19. Rivera B, Miller SR, Brown EM, Price RE. A novel method for endotracheal
intubation of mice and rats used in imaging studies. J Am Assoc Lab Anim
Sci. 2005;44(2):52–5.
20. Ferran AA, Kesteman AS, Toutain PL, Bousquet-Melou A. Pharmacokinetic/
pharmacodynamic analysis of the influence of inoculum size on the selection
of resistance in Escherichia coli by a quinolone in a mouse thigh bacterial
infection model. Antimicrob Agents Chemother. 2009;53(8):3384–90.
21. Kesteman AS, Ferran AA, Perrin-Guyomard A, Laurentie M, Sanders P,
Toutain PL, et al. Influence of inoculum size and marbofloxacin plasma
exposure on the amplification of resistant subpopulations of Klebsiella
pneumoniae in a rat lung infection model. Antimicrob Agents Chemother.
2009;53(11):4740–8.
22. Ferran AA, Toutain PL, Bousquet-Melou A. Impact of early versus later
fluoroquinolone treatment on the clinical; microbiological and resistance
outcomes in a mouse-lung model of Pasteurella multocida infection.
Vet Microbiol. 2011;148(2–4):292–7.
23. Abo-el-Sooud K, Goudah A. Influence of Pasteurella multocida infection on
the pharmacokinetic behavior of marbofloxacin after intravenous and
intramuscular administrations in rabbits. J Vet Pharmacol Ther. 2010;33(1):63–8.
24. Ismail M, El-Kattan Y. Comparative pharmacokinetics of marbofloxacin in
healthy and Mannheimia haemolytica infected calves. Res Vet Sci.
2007;82(3):398–404.
25. Dudhani RV, Turnidge JD, Nation RL, Li J. fAUC/MIC is the most predictive
pharmacokinetic/pharmacodynamic index of colistin against Acinetobacter
baumannii in murine thigh and lung infection models. J Antimicrob
Chemother. 2010;65(9):1984–90.
26. Andes D, Craig WA. In vivo pharmacodynamic activity of the glycopeptide
dalbavancin. Antimicrob Agents Chemother. 2007;51(5):1633–42.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Qu et al. BMC Veterinary Research  (2015) 11:294 Page 7 of 7
